Cohance Lifesciences Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Public

  • Employees
  • 2,811

Employees

  • Stock Symbol
  • 543064

Stock Symbol

  • Investments
  • 7

  • Share Price
  • $4.95
  • (As of Friday Closing)

Cohance Lifesciences General Information

Description

Cohance Lifesciences Ltd is a science-led CRDMO and life sciences company providing contract research, development, and manufacturing services to pharmaceutical, biotechnology, and specialty chemical customers. The company operates as a single reporting segment focused on CDMO services, supported by capabilities in APIs, formulations, antibody-drug conjugates (ADCs), oligonucleotides, and specialty chemicals. It serves customers through an integrated network of manufacturing and R&D facilities across India and the United States, offering end-to-end solutions from development to commercial manufacturing. Geographically, it operates in Europe, USA, India and Rest of the world.

Contact Information

Website
www.cohance.com
Formerly Known As
Suven Pharmaceuticals, Suven Pharma
Ownership Status
Publicly Held
Financing Status
Private Equity-Backed
Corporate Office
  • 202, A-Wing, Galaxy Towers, Plot Number 1, Hyderabad Knowledge City, TSIIC
  • Raidurg, Serilingampally, Rangareddy District
  • Hyderabad, Telangana 500081
  • India
+91 040
Primary Industry
Pharmaceuticals
Other Industries
Other Pharmaceuticals and Biotechnology
Stock Exchange
BOM
Corporate Office
  • 202, A-Wing, Galaxy Towers, Plot Number 1, Hyderabad Knowledge City, TSIIC
  • Raidurg, Serilingampally, Rangareddy District
  • Hyderabad, Telangana 500081
  • India
+91 040

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cohance Lifesciences Stock Performance

As of 20-Nov-2026, Cohance Lifesciences’s stock price is $4.95. Its current market cap is $1.89B with 383M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.95 $4.91 $2.91 - $6.78 $1.89B 383M 135K $0.01

Cohance Lifesciences Financials Summary

As of 30-Sep-2026, Cohance Lifesciences has a trailing 12-month revenue of $222M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2026 31-Mar-2026 FY 2025 31-Mar-2025 FY 2024 31-Mar-2024
EV 1,790,491 1,238,048 3,377,195 1,986,531
Revenue 222,455 249,402 298,759 124,908
EBITDA 25,472 48,242 99,974 56,204
Net Income 5,109 20,283 57,634 36,272
Total Assets 591,370 607,258 640,753 270,394
Total Debt 46,684 42,446 56,808 7,796
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Cohance Lifesciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cohance Lifesciences‘s full profile, request access.

Request a free trial

Cohance Lifesciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Cohance Lifesciences Ltd is a science-led CRDMO and life sciences company providing contract research, development, and
Pharmaceuticals
Hyderabad, India
2,811 As of 2026

Hamburg, Germany
 

Bangalore, India
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cohance Lifesciences Competitors (5)

One of Cohance Lifesciences’s 5 competitors is Evotec, a Formerly PE-Backed company based in Hamburg, Germany.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Evotec Formerly PE-Backed Hamburg, Germany
Syngene International Formerly PE-Backed Bangalore, India
Suven Life Sciences Corporation Hyderabad, India
Sai Life Sciences Formerly VC-backed Hyderabad, India
Divi's Laboratories Corporation Hyderabad, India
You’re viewing 5 of 5 competitors. Get the full list »

Cohance Lifesciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cohance Lifesciences Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Cohance Lifesciences‘s full profile, request access.

Request a free trial

Cohance Lifesciences Investments & Acquisitions (7)

Cohance Lifesciences’s most recent deal was a Later Stage VC with NJ Bio for . The deal was made on 12-Aug-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
NJ Bio 12-Aug-2025 Later Stage VC Other Pharmaceuticals and Biotechnology
NJ Bio 20-Dec-2024 Merger/Acquisition Other Pharmaceuticals and Biotechnology
Sapala 12-Jul-2024 Merger/Acquisition Multi-line Chemicals
RA Chem Pharma 01-Nov-2022 Buyout/LBO Other Pharmaceuticals and Biotechnology
Casper Pharma 05-Apr-2022 Merger/Acquisition Pharmaceuticals
You’re viewing 5 of 7 investments and acquisitions. Get the full list »

Cohance Lifesciences ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

17.22 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Laboratory Equipment and Services

Subindustry

of 67

Rank

Percentile

To view Cohance Lifesciences’s complete esg history, request access »

Cohance Lifesciences Exits (1)

Cohance Lifesciences’s most recent exit was on 07-Mar-2019 from Rising Pharma Holdings. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Rising Pharma Holdings 07-Mar-2019 Completed
To view Cohance Lifesciences’s complete exits history, request access »

Cohance Lifesciences Affiliates

Subsidiaries (3)

Name Industry Location Year Founded
NJ Bio Princeton, NJ 2018
Casper Pharma East Brunswick, NJ 2016
Sapala Hyderabad, India 2005

Cohance Lifesciences FAQs

  • When was Cohance Lifesciences founded?

    Cohance Lifesciences was founded in 2018.

  • Where is Cohance Lifesciences headquartered?

    Cohance Lifesciences is headquartered in Hyderabad, India.

  • What is the size of Cohance Lifesciences?

    Cohance Lifesciences has 2,811 total employees.

  • What industry is Cohance Lifesciences in?

    Cohance Lifesciences’s primary industry is Pharmaceuticals.

  • Is Cohance Lifesciences a private or public company?

    Cohance Lifesciences is a Public company.

  • What is Cohance Lifesciences’s stock symbol?

    The ticker symbol for Cohance Lifesciences is 543064.

  • What is the current stock price of Cohance Lifesciences?

    As of 20-Nov-2026 the stock price of Cohance Lifesciences is $4.95.

  • What is the current market cap of Cohance Lifesciences?

    The current market capitalization of Cohance Lifesciences is $1.89B.

  • What is Cohance Lifesciences’s current revenue?

    The trailing twelve month revenue for Cohance Lifesciences is $222M.

  • Who are Cohance Lifesciences’s competitors?

    Evotec, Syngene International, Suven Life Sciences, Sai Life Sciences, and Divi's Laboratories are competitors of Cohance Lifesciences.

  • What is Cohance Lifesciences’s annual earnings per share (EPS)?

    Cohance Lifesciences’s EPS for 12 months was $0.01.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process